Table 5. Characteristics of malignancy patients among HIV infected patients.
| Characteristics | Total (n = 48) | ADC (n = 20) | NADC (n = 28) | P |
|---|---|---|---|---|
| Median age, yr | 51.5 (44.3–58.8) | 47 (40.3–55.0) | 53 (47.3–61.8) | 0.015 |
| Sex (male) | 45 (93.8) | 18 (90) | 27 (96.4) | 0.563 |
| Median CD4+ T cell count | 249 (27.5–486) | 22 (9–274) | 389 (144–549.3) | < 0.001 |
| Median duration from HIV to cancer, yr | 3.92 (0.08–9.13) | 1.47 (0.02–10.3) | 5.57 (0.2–9.1) | 0.475 |
| HBV co-infection | 10 (22.2) | 4 (21.1) | 6 (23.1) | > 0.999 |
| HCV co-infection | 4 (8.9) | 1 (5.3) | 3 (11.5) | 0.627 |
| First presented as cancer | 19 (39.6) | 9 (45) | 10 (35.7) | 0.517 |
| LTF and presented as cancer | 14 (29.2) | 8 (40) | 6 (21.4) | 0.163 |
| On-HAART patients | 15 (31.3) | 3 (15) | 12 (42.9) | 0.040 |
| CDC categories at enrollment | ||||
| Category A | 19 (43.2) | 3 (16.7) | 16 (61.5) | 0.003 |
| Category B | 11 (25.0) | 4 (22.2) | 7 (26.9) | > 0.999 |
| Category C | 14 (31.8) | 11 (61.1) | 3 (11.5) | 0.001 |
| 5-year survival | 9/33 (28.1) | 4/13 (30.8) | 5/19 (26.3) | > 0.999 |
| 1-year survival | 15/38 (39.5) | 5/14 (35.7) | 10/24 (41.7) | 0.717 |
Values are expressed as number (%) or number (IQR).
HIV = human immunodeficiency virus, ADC = AIDS-defining cancer, NADC = non-AIDS-defining cancer, HBV = hepatitis B virus, HCV = hepatitis C virus, LTF = lost to follow-up, HAART = Highly active antiretroviral therapy, CDC = Centers for Disease Control and Prevention, IQR = interquartile range.